HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results
| HSCS Stock | USD 3.65 0.07 1.88% |
Slightly above 62% of Heart Test's investor base is looking to short. The analysis of overall sentiment of trading Heart Test Laboratories stock suggests that many investors are alarmed at this time. Heart Test's investing sentiment can be driven by a variety of factors including economic data, Heart Test's earnings reports, geopolitical events, and overall market trends.
Southlake, TX, Sept. 12, 2024 -- Heart Test Laboratories, Inc. dba HeartSciences
Read at globenewswire.com
 |
Heart Test Fundamental Analysis
We analyze Heart Test's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Heart Test using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Heart Test based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Book
Price To Book Comparative Analysis
Heart Test is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Heart Test Laboratories Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Heart Test stock to make a market-neutral strategy. Peer analysis of Heart Test could also be used in its relative valuation, which is a method of valuing Heart Test by comparing valuation metrics with similar companies.
Peers
Heart Test Related Equities
| NAOV | NanoVibronix | 7.36 | ||||
| BJDX | Bluejay Diagnostics | 3.73 | ||||
| BBLG | Bone Biologics | 1.38 | ||||
| TIVC | Tivic Health | 0.31 | ||||
| ILAG | Intelligent Living | 1.79 | ||||
| VRAX | Virax Biolabs | 3.90 | ||||
| BIAF | BioAffinity Technologies, | 7.41 | ||||
| VVOS | Vivos Therapeutics | 8.70 |
Additional Tools for Heart Stock Analysis
When running Heart Test's price analysis, check to measure Heart Test's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heart Test is operating at the current time. Most of Heart Test's value examination focuses on studying past and present price action to predict the probability of Heart Test's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Heart Test's price. Additionally, you may evaluate how the addition of Heart Test to your portfolios can decrease your overall portfolio volatility.